Inhibition of proliferative responses by the knockdown of VRK2 is consistent with another report, indicating that higher levels of VRK2 expression are present in a subgroup of primary high-grade astrocytoma cells [77]. This evidence concerns the gene VRK2 and astrocytoma (excluding glioblastoma).